2 results
Approved WMOPending
To investigate the long-term safety, tolerability and acceptability of Nasalfent in the treatment BTCP
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.